Intellia Therapeutics (NTLA) to Release Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) is anticipated to release its Q4 2024 earnings data before the market opens on Thursday, February 27th. Analysts expect Intellia Therapeutics to post earnings of ($1.32) per share and revenue of $8.10 million for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.

Intellia Therapeutics Stock Performance

NASDAQ NTLA traded down $0.77 during trading hours on Friday, hitting $10.09. 4,574,564 shares of the company's stock were exchanged, compared to its average volume of 3,292,691. The firm has a market capitalization of $1.03 billion, a P/E ratio of -1.85 and a beta of 1.80. The business's 50 day moving average is $10.90 and its 200-day moving average is $15.72. Intellia Therapeutics has a 12-month low of $8.96 and a 12-month high of $34.87.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the firm's stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders have sold 29,000 shares of company stock valued at $352,551. Company insiders own 3.20% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on NTLA. Chardan Capital dropped their price target on shares of Intellia Therapeutics from $91.00 to $68.00 and set a "buy" rating for the company in a research report on Friday. JPMorgan Chase & Co. restated a "neutral" rating and set a $13.00 price objective (down from $45.00) on shares of Intellia Therapeutics in a report on Friday. Wells Fargo & Company reduced their target price on Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday. BMO Capital Markets dropped their price target on Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating for the company in a research note on Friday, January 10th. Finally, Citigroup raised their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a "neutral" rating in a report on Friday. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $42.12.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.